CUMYL-4CN-BINACA

CUMYL-4CN-BINACA is a synthetic cannabinoid that has been identified in illicit products and associated with serious adverse events. It is a potent agonist for the CB1 receptor, with a reported potency 7.5 times greater than that of the potent synthetic cannabinoid JWH-018.

Chemistry

CUMYL-4CN-BINACA is a member of the class of indazole-3-carboxamides, which are synthetic cannabinoids. It is structurally related to other synthetic cannabinoids such as 5F-ADB, AB-CHMINACA, and AB-FUBINACA. The compound has a cumyl group, a 4-cyanobutyl group, and a N-1-naphthyl group.

Pharmacology

CUMYL-4CN-BINACA is a potent agonist for the CB1 receptor, with a reported potency 7.5 times greater than that of the potent synthetic cannabinoid JWH-018. It is believed to produce its effects by binding to and activating the CB1 receptor, which is found primarily in the brain. This can result in a range of effects, including euphoria, altered perception, and adverse effects such as anxiety and paranoia.

Adverse effects

Adverse effects associated with CUMYL-4CN-BINACA use include tachycardia, hypertension, seizures, and severe agitation. There have also been reports of death associated with its use.

Legal status

CUMYL-4CN-BINACA is a controlled substance in several countries, including the United States, where it is a Schedule I controlled substance. It is also controlled under the UN Convention on Psychotropic Substances.

See also

• Synthetic cannabinoids
• Cannabinoid receptor
• Indazole

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia